|
|
T2 Biosystems Announces Second Largest Sepsis-Driven Instrument Sale in Company History
|
|
|
T2 Biosystems Announces First Quarter 2023 Financial Results
|
|
|
T2 Biosystems Announces Exploration of Strategic Alternatives and the Implementation of a Restructuring Program
|
|
|
T2 Biosystems Announces FDA 510(k) Submission for the T2Biothreat Panel
|
|
|
T2 Biosystems Reschedules First Quarter 2023 Financial Results Reporting to May 23, 2023
|
|
|
T2 Biosystems Reschedules First Quarter 2023 Financial Results Reporting to May 22, 2023
|
|
|
T2 Biosystems Postpones Reporting of First Quarter 2023 Financial Results
|
|
|
T2 Biosystems to Report First Quarter 2023 Financial Results on May 15, 2023
|
|
|
T2 Biosystems Highlights New Clinical Data Presented at the ECCMID 2023 Conference
|
|
|
T2 Biosystems Announces Webinar and White Paper Highlighting T2Candida Panel Clinical Data and Best Practices
|
